The ability to characterize melanoma at the molecular level reduces the need for SLNb, a surgical procedure that carries a risk of complications.7 Our approach of combining CP factors with molecular profiling better identifies patients who may forgo the SLNb procedure because of their low risk of metastasis. Here, CP is linked to melanoma.